Price
Target price
€0.39
€0.39
-
-
-
-
28.01.23 / Tradegate
WKN: A3CV9C / Name: Altamira Therapeutics / Stock / Small Cap /
We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Summary Altamira Therapeutics
Altamira Therapeutics (WKN A3CV9C), formerly known as MEI Pharma, Inc., is a multinational pharmaceutical company listed on the stock market, focusing on the development of novel therapeutic solutions. With a vision to improve patients' lives through innovative treatment approaches, Altamira Therapeutics ventures into unexplored territories of drug research and development. Let's dive into the dynamics of this company, its products, and the reasons behind the growing investor interest.
The Company's Origins and Expansion
Founded in 2000, and headquartered in San Diego, California, Altamira Therapeutics has made significant strides in pharmaceutical innovation. The company's repertoire encompasses a wide array of drug candidates that are either in clinical or preclinical stages of development. These prospective drugs target various diseases, such as cancer, autoimmune disorders, and viral infections.
Over the years, Altamira has forged partnerships and collaborations with prominent names in the pharmaceutical landscape. Remarkable partners include Helsinn Healthcare, Kyowa Hakko Kirin, and Presage Biosciences. These alliances have facilitated the expansion of the company's drug development pipeline and expanded its global reach.
Altamira's Therapeutic Pipeline
The drug pipeline of Altamira Therapeutics touts a diverse range of promising assets. Let's delve into some of these essential components:
- Pracinostat: An oral histone deacetylase (HDAC) inhibitor, which is currently in the clinical evaluation phase as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). HDAC inhibitors are known to exhibit anti-cancer properties by triggering cell cycle arrest, promoting apoptosis, and inhibiting angiogenesis.
- ME-401: An oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor being assessed for its efficacy in relapsed/refractory follicular lymphoma. It has demonstrated promising results in early-phase clinical trials and was granted Fast Track status by the US Food and Drug Administration (FDA) in 2019.
- ME-344: A mitochondrial inhibitor with potential application in ovarian cancer treatment. Early clinical trials have yielded encouraging results, and the drug is now awaiting further evaluation.
- Voruciclib: An oral cyclin-dependent kinase (CDK) inhibitor targeting hematologic malignancies and solid tumors is still in preclinical evaluation. Ongoing in vitro and animal studies are assessing its anti-cancer potential.
Noteworthy Milestones and Financials
Altamira Therapeutics has secured several strategic milestones critical to a pharmaceutical company's growth. These encompass successful IPOs, drug candidates securing FDA Fast Track Designation, and securing exclusive licensing agreements to global rights for promising drugs.
As with any publicly traded company, financial performance is of vital importance. Recent financial statements have shown substantial progress, with an increased cash flow and secure resources to proceed with ongoing and upcoming clinical trials. This financial stability allows Altamira to continue its mission of developing innovative therapeutic solutions that address unmet medical needs.
Entering into the world of pharmaceutical investments can be tricky. High levels of volatility and an uncertain regulatory landscape are just a couple of the factors that make this sector inherently risky. In these challenging waters, why should you consider Altamira Therapeutics?
It's no secret that Altamira's drug pipeline exhibits vast promise. The company's investment in cutting-edge research and its expanding portfolio of drug candidates has garnered significant interest from investors and industry experts.
Another significant factor driving its appeal is the partnerships with reputed pharmaceutical giants. This collaborative approach fosters knowledge sharing and accelerated drug development, potentially culminating in ground-breaking therapies.
Finally, the company boasts strong financials, assuring investors that Altamira Therapeutics is well-positioned to continue investing in research and development. This fiscal stability is pivotal in weathering the uncertain environment surrounding drug development.
Conclusion
In a nutshell, Altamira Therapeutics stands as a formidable player in the pharmaceutical industry. Its innovative drug development pipeline, potent collaborations, and robust financial health promise a bright future. However, it's essential to consider potential risks associated with investing in pharmaceutical companies. As an investor, conducting thorough research, and consulting financial experts become necessary steps in the decision-making process. If you're contemplating whether to include Altamira Therapeutics in your investment portfolio, make sure to weigh the pros and cons before taking the plunge.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Altamira Therapeutics Ltd. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Altamira Therapeutics
sharewise wants to provide you with the best news and tools for Altamira Therapeutics, so we directly link to the best financial data sources.